Mydecine Financial Statements From 2010 to 2024
| MYCOF Stock | USD 0 0 44.00% |
Check Mydecine Innovations financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Mydecine Innovations' main balance sheet or income statement drivers, such as , as well as many indicators such as . Mydecine financial statements analysis is a perfect complement when working with Mydecine Innovations Valuation or Volatility modules.
Mydecine |
Mydecine Innovations Group Company Return On Asset Analysis
Mydecine Innovations' Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Mydecine Innovations Return On Asset | -1.76 |
Most of Mydecine Innovations' fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Mydecine Innovations Group is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Based on the latest financial disclosure, Mydecine Innovations Group has a Return On Asset of -1.7615. This is 79.87% lower than that of the Healthcare sector and significantly lower than that of the Drug Manufacturers—Specialty & Generic industry. The return on asset for all United States stocks is notably higher than that of the company.
Mydecine Innovations Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Mydecine Innovations's current stock value. Our valuation model uses many indicators to compare Mydecine Innovations value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Mydecine Innovations competition to find correlations between indicators driving Mydecine Innovations's intrinsic value. More Info.Mydecine Innovations Group is regarded second in return on equity category among its peers. It is considered to be number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Mydecine Innovations' earnings, one of the primary drivers of an investment's value.About Mydecine Innovations Financial Statements
Mydecine Innovations stakeholders use historical fundamental indicators, such as Mydecine Innovations' revenue or net income, to determine how well the company is positioned to perform in the future. Although Mydecine Innovations investors may analyze each financial statement separately, they are all interrelated. For example, changes in Mydecine Innovations' assets and liabilities are reflected in the revenues and expenses on Mydecine Innovations' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Mydecine Innovations Group. Please read more on our technical analysis and fundamental analysis pages.
Mydecine Innovations Group Inc., a biotech and life sciences company, engages in the development and commercialization of drugs for treating mental health problems. Mydecine Innovations Group Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada. Mydecine Innovations operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 11 people.
Currently Active Assets on Macroaxis
Other Information on Investing in Mydecine Pink Sheet
Mydecine Innovations financial ratios help investors to determine whether Mydecine Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Mydecine with respect to the benefits of owning Mydecine Innovations security.